Not yet recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
NCT07900633· Phase 3· Eli Lilly and Company· Source
Contact: Patrick Morgante (principal investigator)
Recruiting
A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
NCT07816367· Phase 3· TriGemX Bio, Inc.· Source
Contact: Patrick Morgante
Recruiting
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
NCT07794579· Phase 3· Eli Lilly and Company· Source
Contact: Patrick Morgante (principal investigator)
Recruiting
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
NCT07684144· Phase 3· Amgen· Source
Recruiting
Phase 3 Pivotal Trial Comparing CARTISTEM® and Surgical Comparator for Knee Cartilage Lesions and Osteoarthritis
NCT07339111· Phase 3· Medipost, Inc.· Source
Contact: Millicent Clark
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600· Phase 3· Eli Lilly and Company· Source
Contact: Patrick Morgante (principal investigator)
Recruiting
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229· Phase 3· Bristol-Myers Squibb· Source
Contact: Patrick Morgante, Site 2608
Recruiting
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
NCT07231419· Phase 3· Vertex Pharmaceuticals Incorporated· Source
Active, not recruiting
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433· Phase 3· Amgen· Source
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
NCT07011745· Phase 3· Bristol-Myers Squibb· Source
Contact: Patrick Morgante, Site 2608
Active, not recruiting
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858878· Phase 3· Amgen· Source
Recruiting
A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee
NCT06884865· Phase 2· Pacira Pharmaceuticals, Inc· Source
Contact: Millicent Clark
Active, not recruiting
Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
NCT06696443· Phase 3· Vertex Pharmaceuticals Incorporated· Source
Recruiting
DermaSensor Postmarket Surveillance Study
NCT06666790· DermaSensor, Inc.· Source
Contact: Luke Snedaker
Recruiting
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
NCT06628908· Phase 3· Vertex Pharmaceuticals Incorporated· Source
Recruiting
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source
Contact: Patrick Morgante, Site 1215
Active, not recruiting
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390· Phase 3· Eli Lilly and Company· Source
Recruiting
A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
NCT06112418· Cleerly, Inc.· Source
Contact: Ryann Sardinia
Active, not recruiting
ZILRETTA in Subjects With Shoulder Osteoarthritis
NCT06269705· Phase 3· Pacira Pharmaceuticals, Inc· Source
Active, not recruiting
Safety and Pharmacodynamics of GNSC-001 Intra-articular Injection for Knee Osteoarthritis
NCT05835895· Phase 1· Genascence Corporation· Source